Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the mend as you type.
providing the next PR doesn't suggest they will exercise a pre approved stock split
It's a shakedown. Afeckin good one too
We will find out how much folks believe after today. Thats for sure. lol
GLTU
why? Do you think they bought the shares to sell right away?
Wouldn't they want to profit from their investment?
Maybe now they won't split the stock. This is a nice chunk of change to play with. Very nice news.
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
Date : 01/04/2010 @ 8:30AM
Source : Business Wire
Stock : NeoPharm, Inc. (NEOL)
Quote : 0.29 0.0 (0.00%) @ 7:52AM
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly disease of the lungs in humans with very high morbidity. There is currently no proven effective treatment for the cure of this disease
The studies that NeoPharm has performed in animals and in ex-vivo human tissue have shown that the receptors for interleukin 13 (IL13) are significantly over-expressed in pulmonary fibroblasts. The recombinant protein, IL13-PE, has demonstrated selective cytotoxicity to the IL13 receptor-expressing fibroblasts, thereby ameliorating the histopathological evidence of IPF in animal models
In this Phase I clinical study, the IL13-PE will be administered into the lungs as an inhaled, aerosolized liquid. Six doses of the drug with sequential increment will be administered in a total of 32 patients. The objective of the study is to assess the safety and the maximum tolerated dose, along with efficacy in patients with advanced IPF
Dr. Aquilur Rahman, President and CEO commented, “The submission of this IND is a major milestone for the Company. We anticipate conducting this study through a collaboration with IPFnet, a collaborative group of clinical sites formed under the auspices of National Heart Lung and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH). It is expected that six to eight sites will be performing these clinical studies with the coordinating center role being assumed by the Duke Clinical Research Institute (DCRI)”. Dr. Rahman further commented, “We are fortunate to have these prestigious centers interested in our clinical trials to hopefully make a difference in the survival and quality of life for these extremely sick patients”
About NeoPharm, Inc. NeoPharm, Inc., based in Lake Bluff, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer and other drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm’s web site at www.neopharm.com
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "projects," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development programs including, but not limited to, the development of IL13-PE, the initiation, progress, and outcomes of clinical trials of the Company's drug product candidates including, but not limited to IL13-PE, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to difficulties or delays that may arise in the development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds, including, but not limited to, IL13-PE, the Company's possible need to reduce its funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug product candidates, including, but not limited to, IL13-PE, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to commercialize any of its drug product candidates, including, but not limited to, IL13-PE, and other risks of the type previously detailed from time to time in filings the Company formerly made with the Securities and Exchange Commission ("SEC"). Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. At the Company's request, the Company's obligation to file reports with the SEC was suspended effective February 12, 2009. For the foregoing reasons, you should not rely on these forward-looking statements or our previously filed SEC reports as a prediction of actual future results
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
Date : 01/04/2010 @ 8:30AM
Source : Business Wire
Stock : NeoPharm, Inc. (NEOL)
Quote : 0.29 0.0 (0.00%) @ 7:52AM
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly disease of the lungs in humans with very high morbidity. There is currently no proven effective treatment for the cure of this disease
The studies that NeoPharm has performed in animals and in ex-vivo human tissue have shown that the receptors for interleukin 13 (IL13) are significantly over-expressed in pulmonary fibroblasts. The recombinant protein, IL13-PE, has demonstrated selective cytotoxicity to the IL13 receptor-expressing fibroblasts, thereby ameliorating the histopathological evidence of IPF in animal models
In this Phase I clinical study, the IL13-PE will be administered into the lungs as an inhaled, aerosolized liquid. Six doses of the drug with sequential increment will be administered in a total of 32 patients. The objective of the study is to assess the safety and the maximum tolerated dose, along with efficacy in patients with advanced IPF
Dr. Aquilur Rahman, President and CEO commented, “The submission of this IND is a major milestone for the Company. We anticipate conducting this study through a collaboration with IPFnet, a collaborative group of clinical sites formed under the auspices of National Heart Lung and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH). It is expected that six to eight sites will be performing these clinical studies with the coordinating center role being assumed by the Duke Clinical Research Institute (DCRI)”. Dr. Rahman further commented, “We are fortunate to have these prestigious centers interested in our clinical trials to hopefully make a difference in the survival and quality of life for these extremely sick patients”
About NeoPharm, Inc. NeoPharm, Inc., based in Lake Bluff, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer and other drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm’s web site at www.neopharm.com
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "projects," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development programs including, but not limited to, the development of IL13-PE, the initiation, progress, and outcomes of clinical trials of the Company's drug product candidates including, but not limited to IL13-PE, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to difficulties or delays that may arise in the development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds, including, but not limited to, IL13-PE, the Company's possible need to reduce its funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug product candidates, including, but not limited to, IL13-PE, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to commercialize any of its drug product candidates, including, but not limited to, IL13-PE, and other risks of the type previously detailed from time to time in filings the Company formerly made with the Securities and Exchange Commission ("SEC"). Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. At the Company's request, the Company's obligation to file reports with the SEC was suspended effective February 12, 2009. For the foregoing reasons, you should not rely on these forward-looking statements or our previously filed SEC reports as a prediction of actual future results
Roger that. ANX nice filing. BNVI up premkt.
ANX news out. They filed NDA for anx530.
If we are gonna spike up, it's gonna happen premkt. Just like it does with every other stock. If it doesn't, it's gonna be a long day.
EOM
Stock traitor, whats your bag? all you do is bring stories that no one can corroborate. No trust in you. Excitement is one thing, Rumors are another. Booooooooo
EOM
Happy New Year Nathanial. It's moving cause we own it. We are good. lol
All the best this new year to you.
Greggor
Happy New Year buddy. It's gonna be a great year. I see big green on our horizion.
Best of luck as always
Happy New Year ya bunch of Rats.
I love ya.
I remember you calling for a gap fill yesterday @ .32
Excellent call.
Happy New Year BBB Hope all your trades are winners.
I have my sneakers on today. Might be the only way to keep up with the run she is going to go on.. JMO
Nike cross trainers. I'll chase this bad boy up hill if I have too.
ETRM had a nice move yesterday. @.62 it is down from $5.60 HOY
but it moved up 60% yesterday.
keep an eye on this one. It is trading in premkt. up .01c
37 mil O/S
I'm with ya. I held this for a while, then sold. I was in @.41
I would like to have those back now please. lol
This could very well be the shot in the arm this stock has been looking for .
Happy New Year.
Anyone pick up some DARA yesterday? It looks to continue. IMO They have requested an IPO of a private company they own shares in. Surgivision. They have a colaboration with Seimens for some type of MRI machine, and software.
If this IPO is allowed, it could mean good things for DARA. Hence the increase in PPS on speculation.
Happy New Year everybody.
morning Camaro, I did not get in DARA, though I am thinking now I should have. It is looking very strong. I think the hype is about the potental value of thier IPO. Surgivision.
Don't know how far it will carry the stock. but it looks like .50 is going to at be the open today. If not more.
DARA and MSBT both made a little move yesterday. DARA looks quite good at this level.
Thanks for the info MlKR,
MSBT, DARA runnuni today
Thanks Bank. Happy Holidays.
MSBT making a move
Exellent. SPMI time to buy is today.
It's setting up for another blastoff. vol. is rolling
for sure.
look @ MSBT and DARA for giggles.
DARA up 9%
link back. lol
how are ya Bigs?
time for some explosiveness. Starp in
EOM
lol funny. They already have manufacturing in place as part of the NDA requirement.
MIGL. It's time to sit on the bid and pick any up under .45
I shoulda held on to my shares. Now I'll have to buy back at higher price. If they okay an IPO, this will fly up. IMO SurgiVision has some neat tech, and works with Seimens.
I am watching DARA very close today
Nice, precise, and to the point. Thanks for the article. I imagine we will have a volatile day w/o news.
Thats part of the trade with all these bio's
good luck if your holding-selling- or buying.
they all seem to be a logical move today. hehehehehehehehehehe
DARA may be getting window dressed or just getting a boost. @ .4001 from .37 yesterday. it can go to .50 pretty easy.
best to all
PRE MARKET ALERT
DARA had a nice vol. day yesterday, and was up 10%
Amex, ULU 2nd day of premkt activity. vol spike yesterday. up .03 in premkt to .26
Have a great day all
ULU showing a continuation. up .03 in premkt.
A few of us came from a new board. Please come and share.
Greggor
http://investorshub.advfn.com/boards/board.aspx?board_id=16653
Yes, SPMI 5 mil O/S one to watch.